Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Clinical, Immunological and Molecular Findings of Patients with Severe Combined Immunodeficiency: Introducing of 7 Novel Mutations in 7 Genes

View through CrossRef
Abstract Purpose Severe combined immunodeficiency (SCID) is one of the severe inborn errors of the immune system associated with life-threatening infections. This disorder is characterized by diminished cellular and humoral immunity. A variable phenotype, including atypical and leaky SCID cases, as well as the heterogeneity in its genetic basis, may lead to a significant delay in diagnosis. Therefore, early diagnosis of SCID patients is crucial. Here, we describe the clinical manifestations and genetic results of four patients with SCID and four patients with atypical SCID. Methods Eight patients, who were clinically suspected to SCID, underwent immunological evaluations and genetic studies. Whole Exome Sequencing (WES) was used to identify the most relevant genetic defects which are responsible for the patients’ clinical phenotype. Further, the identified mutations were evaluated by Sanger sequencing in patients and their parents. Results All patients (4 males and 4 females) presented SCID phenotype in early infancy within 6 months of life. We found eight mutations, including two novel mutations in RAG2 (p.I273T, p.G44X), a novel 2-bp deletion in IL7R (p.F361WfsX17), a novel 2-bp deletion in LAT (p.Y207fs), a novel mutation in ADA (c.780 + 1G > A), a novel mutation in JAK3 (p.Q228Ter), a novel mutation in LIG4 (p.G428R), and also a previously reported missense mutation in RAG1 (p.A444V). All patients were homozygous, and their parents were heterozygous. Conclusion The results of our study expand the clinical and molecular spectrum associated with SCID and leaky SCID phenotypes and provide valuable information for the clinical management of our patients.
Title: Clinical, Immunological and Molecular Findings of Patients with Severe Combined Immunodeficiency: Introducing of 7 Novel Mutations in 7 Genes
Description:
Abstract Purpose Severe combined immunodeficiency (SCID) is one of the severe inborn errors of the immune system associated with life-threatening infections.
This disorder is characterized by diminished cellular and humoral immunity.
A variable phenotype, including atypical and leaky SCID cases, as well as the heterogeneity in its genetic basis, may lead to a significant delay in diagnosis.
Therefore, early diagnosis of SCID patients is crucial.
Here, we describe the clinical manifestations and genetic results of four patients with SCID and four patients with atypical SCID.
Methods Eight patients, who were clinically suspected to SCID, underwent immunological evaluations and genetic studies.
Whole Exome Sequencing (WES) was used to identify the most relevant genetic defects which are responsible for the patients’ clinical phenotype.
Further, the identified mutations were evaluated by Sanger sequencing in patients and their parents.
Results All patients (4 males and 4 females) presented SCID phenotype in early infancy within 6 months of life.
We found eight mutations, including two novel mutations in RAG2 (p.
I273T, p.
G44X), a novel 2-bp deletion in IL7R (p.
F361WfsX17), a novel 2-bp deletion in LAT (p.
Y207fs), a novel mutation in ADA (c.
780 + 1G > A), a novel mutation in JAK3 (p.
Q228Ter), a novel mutation in LIG4 (p.
G428R), and also a previously reported missense mutation in RAG1 (p.
A444V).
All patients were homozygous, and their parents were heterozygous.
Conclusion The results of our study expand the clinical and molecular spectrum associated with SCID and leaky SCID phenotypes and provide valuable information for the clinical management of our patients.

Related Results

Dynamics of Mutations in Patients with ET Treated with Imetelstat
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Abstract Background: Imetelstat, a first in class specific telomerase inhibitor, induced hematologic responses in all patients (pts) with essential thrombocythemia (...
Clinical and Biological Implications of CUX1 Mutations in Myeloid Neoplasms
Clinical and Biological Implications of CUX1 Mutations in Myeloid Neoplasms
Abstract Recurrent somatic mutations of CUX1 are described in myeloid neoplasms. CUX1 is located at chromosome 7q22.1; -7/del(7q) involving CUX1 locus are common abn...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract Introduction Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Somatic mutations and T-cell clonality in patients with immunodeficiency
Somatic mutations and T-cell clonality in patients with immunodeficiency
Common variable immunodeficiency and other late-onset immunodeficiencies often co-manifest with autoimmunity and lymphoproliferation. The pathogenesis of most cases is elusive, as ...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Analysis of Molecular Minimal Residual Disease in Patients with Acute Leukemia during Complete Remission
Analysis of Molecular Minimal Residual Disease in Patients with Acute Leukemia during Complete Remission
Abstract Introduction: Acute leukemia is a group of clonal heterogeneous diseases with high recurrence rate. The monitoring of minimal residual disease (MRD) after t...

Back to Top